GenSight received MHRA approval for testing Gene Therapy + Device in Retinitis Pigmentosa. May test patients with dry AMD

(c) GenSight Biologics

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK Medicines and Healthcare Regulatory Agency (MHRA) acceptance of the Company’s Clinical Trial Application (CTA) to initiate the PIONEER Phase I/II study of GS030 in patients with Retinitis Pigmentosa (RP).

Artificial Intelligence can predict blood pressure, age and smoking status based on retinal image

(c) Paul Parker/SPL via Nature

Eyes are said to be the window to the soul — but researchers at Google see them as indicators of a person’s health. The technology giant is using deep learning to predict a person’s blood pressure, age and smoking status by analyzing a photograph of their retina. Google’s computers glean clues from the arrangement of blood vessels — and a preliminary study suggests that the machines can use this information to predict whether someone is at risk of an impending heart attack.